Recent Quotes (30 days)

You have no recent quotes
chg | %

Viking Therapeutics Inc  

(Public, NASDAQ:VKTX)   Watch this stock  
Find more results for VKTX
2.93
+0.16 (5.78%)
Nov 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.71 - 2.97
52 week 0.88 - 3.24
Open 2.77
Vol / Avg. 311,064.00/803,408.00
Mkt cap 83.50M
P/E     -
Div/yield     -
EPS -0.83
Shares 28.50M
Beta     -
Inst. own 7%
Nov 8, 2017
Q3 2017 Viking Therapeutics Inc Earnings Call
Nov 8, 2017
Q3 2017 Viking Therapeutics Inc Earnings Release
Sep 12, 2017
Viking Therapeutics Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -140.76% -98.29%
Return on average equity -293.52% -175.71%
Employees 4 -
CDP Score - -

Address

12340 El Camino Real Ste 250
SAN DIEGO, CA 92130-3093
United States - Map
+1-858-7044660 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Officers and directors

Lawson Macartney Ph.D. Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Brian W. Lian Ph.D. President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Michael Morneau Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Amy Broidrick Senior Vice President - Corporate Development
Bio & Compensation  - Reuters
Gregory S. Zante CPA Vice President - Finance and Operations
Age: 42
Bio & Compensation  - Reuters
Catherine Lee Kelleher M.D. Vice President - Clinical Development
Bio & Compensation  - Reuters
Matthew W. Foehr Director
Age: 44
Bio & Compensation  - Reuters
Charles A. Rowland Jr. Director
Age: 58
Bio & Compensation  - Reuters
Matthew Singleton Independent Director
Bio & Compensation  - Reuters
Stephen W. Webster Independent Director
Age: 56
Bio & Compensation  - Reuters